Key Takeaways Dell and Nvidia will together provide architecture for the next set of supercomputers, named Doudna, for the US Department of Energy. Dell will focus more on sustainable hardware and cooling systems, while Nvidia will provide its AI architecture, including the Vera Rubin AI chips. The US Department of Energy wants to focus more on the sustainable development of AI, hence the choice of environment-conscious companies. The US Department of Energy said that Dell’s next batch of supercomputers will be delivered with Nvidia’s ‘Vera Rubin’ AI chips, marking the beginning of a new era of AI dominance in research. The said systems are expected to be 10x faster than the current batch of supercomputers, which HP provided. The supercomputer will be named ‘Doudna,’ after Jennifer Doudna, a Nobel Prize winner who made key contributions in CRISPR gene-editing. Supercomputers have been instrumental in key scientific discoveries in the last few decades and also played a big role in the design and maintenance of the U.S. nuclear weapons arsenal. And now, with the introduction of artificial intelligence, we’re heading towards a new decade of faster and more efficient scientific research. It (supercomputers) is the foundation of scientific discovery for our country. It is also a foundation for economic and technological leadership. And with that, national security – Nvidia CEO, Jensen Huang Dell Going All in on AI This isn’t the first time Dell and Nvidia have come together to develop newer AI solutions. Back in March 2024, Dell announced the Dell AI Factory with NVIDIA, an end-to-end enterprise AI solution designed for businesses.  This joint venture used Dell’s infrastructure, such as servers, storage, and networking, combined with NVIDIA’s AI architecture and technologies such as GPUs, DPUs, and AI software. Image Credit – Dell For instance, the Dell PowerEdge server uses NVIDIA’s full AI stack to provide enterprises with solutions required for a wide range of AI applications, including speech recognition, cybersecurity, recommendation systems, and language-based services. The demand for Dell’s AI servers has also increased, reaching $12.1B in the first quarter of 2025, with a total backlog of $14.4B, which suggests a strong future demand and order book. The company has set a bold profit forecast between $28.5B and $29.5B, as against the analysts’ prediction of $ 25.05 B. With Doudna, Dell is well-positioned to lead the next generation of supercomputers in AI research, invention, and discoveries. Focus on Energy Efficiency Seagate has warned about the unprecedented increase in demand for AI data storage in the coming few years, which is a significant challenge to the sustainability of AI data centers. Global data volume is expected to increase threefold by 2028.  Image Credit – DIGITIMES Asian The data storage industry currently produces only 1-2 zettabytes (1 zettabyte equals 1 trillion gigabytes) of storage annually, which is much lower than what would be required in the next 4-5 years. At the same time, Goldman Sachs predicts that power requirements will also go up by 165% by 2030 due to increasing demand for AI data centers. This calls for a more sustainable approach for the supercomputing industry as well.  Dell will use its proprietary technologies, such as Direct Liquid Cooling, the PowerCool eRDHx, and Smart Flow design in the Doudna, ensuring energy efficiency. Direct Liquid Cooling (DLC) increased computing density by supporting more cores per rack, which reduces cooling costs by as much as 45%. Dell’s PowerCool eRDHx is a self-contained airflow design that can capture 100% of the heat generated by IT systems. This reduces the dependency on expensive chillers, as eRDHx can work in usual temperatures of 32 and 36 degrees Celsius, leading to 60% savings in cooling energy costs. Lastly, the Dell Smart Flow design improves airflow within IT components and reduces the fan power by 52%. This leads to better performance with fewer cooling requirements. Besides this, Dell plans to incorporate Leak Sense Technology. If a coolant leak occurs, the system’s leak sensor will log an alert in the iDRAC system so that swift action can be taken. As per a report titled ‘Energy and AI’ by the IEA, the data center electricity demand will increase to 945 terawatt-hours (TWh) by 2030. For comparison, this is more than the total electricity consumption of Japan today. The US alone will consume more electricity in 2030 for processing data than for manufacturing all energy-intensive goods combined, including aluminum, steel, cement, and chemicals. Therefore, the need to develop sustainable AI data centers and supercomputers cannot be highlighted enough. Dell’s technology-focused, sustainable approach can be a pivotal point in how efficiently we use AI in the next decade. The US Department of Energy’s choice of Dell also seems to be a conscious move to shift towards companies that give importance to sustainability and can vouch for the long-term viability of research-intensive AI setups. Krishi is a seasoned tech journalist with over four years of experience writing about PC hardware, consumer technology, and artificial intelligence.  Clarity and accessibility are at the core of Krishi’s writing style. He believes technology writing should empower readers—not confuse them—and he’s committed to ensuring his content is always easy to understand without sacrificing accuracy or depth. Over the years, Krishi has contributed to some of the most reputable names in the industry, including Techopedia, TechRadar, and Tom’s Guide. A man of many talents, Krishi has also proven his mettle as a crypto writer, tackling complex topics with both ease and zeal. His work spans various formats—from in-depth explainers and news coverage to feature pieces and buying guides.  Behind the scenes, Krishi operates from a dual-monitor setup (including a 29-inch LG UltraWide) that’s always buzzing with news feeds, technical documentation, and research notes, as well as the occasional gaming sessions that keep him fresh.  Krishi thrives on staying current, always ready to dive into the latest announcements, industry shifts, and their far-reaching impacts.  When he's not deep into research on the latest PC hardware news, Krishi would love to chat with you about day trading and the financial markets—oh! And cricket, as well. View all articles by Krishi Chowdhary Our editorial process The Tech Report editorial policy is centered on providing helpful, accurate content that offers real value to our readers. We only work with experienced writers who have specific knowledge in the topics they cover, including latest developments in technology, online privacy, cryptocurrencies, software, and more. Our editorial policy ensures that each topic is researched and curated by our in-house editors. We maintain rigorous journalistic standards, and every article is 100% written by real authors.

Researchers used the popular gene-editing technique CRISPR to modify the DNA sequences of house spiders, causing them to produce red fluorescent silk.Scientists are hoping that the US Navy and Air Force-funded research could lead to the development of new "supermaterials" produced by arachnids, Fast Company reports.As detailed in a paper published in the journal Angewandte Chemie, a team of researchers at the University of Bayreuth in Germany injected the eggs of unfertilized female spiders with a CRISPR-Cas9 solution to insert a gene sequence for a red fluorescent protein. After mating with males of the same species, the offspring produced red, fluorescent silk, demonstrating that the experiment had been successful."Considering the wide range of possible applications, it is surprising that there have been no studies to date using CRISPR-Cas9 in spiders," said senior author and University of Bayreuth professor Thomas Scheibel in a statement. "We have demonstrated, for the first time worldwide, that CRISPR-Cas9 can be used to incorporate a desired sequence into spider silk proteins, thereby enabling the functionalisation of these silk fibres."Apart from turning their silk bright red, the researchers also attempted to knock out a gene called sine oculis, which is responsible for the development of spider eyes. They found that the gene edit caused total or partial eye loss in experiments, highlighting its important role in visual development.By applying CRISPR-Cas9, a technique that has already been widely used to create custom medical treatments or make farm animals more resilient to diseases, the researchers are hoping to come up with a new generation of silk fibers."Successful spider silk engineering in vivo will, therefore, help to develop and employ new fiber functionalities for a broad range of applications," the team wrote in its paper. "So far, genetic modifications in spiders have been only aimed at evolutionary and developmental research."As Fast Company points out, materials scientists have already been investigating the tactile strength of the silk produced by gene-modified silkworms. But thanks to cutting-edge gene-editing techniques, researchers could soon harness the unique advantages of spider silk as well.While the researchers didn't single out specific use cases for future "supermaterials," the possible applications are practically endless, from lightweight body armor to ultralight running shoes."The ability to apply CRISPR gene-editing to spider silk is very promising for materials science research — for example, it could be used to further increase the already high tensile strength of spider silk," Scheibel explained.Share This Article

Nature, Published online: 30 May 2025; doi:10.1038/d41586-025-01653-4Mutation in an enzyme leads to resistance to chronic and acute pain, according to research in mice.

What just happened? The Department of Energy has announced plans for a new supercomputer designed to significantly accelerate research across a wide range of scientific fields. The initiative highlights the growing convergence between commercial AI development and the computational demands of cutting-edge scientific discovery. The advanced system, to be housed at Lawrence Berkeley National Laboratory and scheduled to become operational in 2026, will be named "Doudna" in honor of Nobel laureate Jennifer Doudna, whose groundbreaking work on CRISPR gene editing has revolutionized molecular biology. Dell Technologies has been selected to deliver the Doudna supercomputer, marking a significant shift in the landscape of government-funded high-performance computing. While companies like Hewlett Packard Enterprise have traditionally dominated this space, Dell's successful bid signals a new chapter. "A big win for Dell," said Addison Snell, CEO of Intersect360 Research, in an interview with The New York Times, noting the company's historically limited presence in this domain. Dell executives explained that the Doudna project enabled them to move beyond the longstanding practice of building custom systems for individual laboratories. Instead, they focused on developing a flexible platform capable of serving a broad array of users. "This market had shifted into some form of autopilot. What we did was disengage the autopilot," said Paul Perez, senior vice president and technology fellow at Dell. The Perlmutter supercomputer at the National Energy Research Scientific Computing Center at Lawrence Berkeley National Laboratory. A defining feature of Doudna will be its use of Nvidia's Vera Rubin platform, engineered to combine the strengths of traditional scientific simulations with the power of modern AI. Unlike previous Department of Energy supercomputers, which relied on processors from Intel or AMD, Doudna will incorporate a general-purpose Arm-based CPU from Nvidia, paired with the company's Rubin AI chips designed specifically for artificial intelligence and simulation workloads. // Related Stories The architecture aims to meet the needs of the laboratory's 11,000 users, who increasingly depend on both high-precision modeling and rapid AI-driven data analysis. Jensen Huang, founder and CEO of Nvidia, described the new system with enthusiasm. "Doudna is a time machine for science – compressing years of discovery into days," he said, adding that it will let "scientists delve deeper and think bigger to seek the fundamental truths of the universe." In terms of performance, Doudna is expected to be over 10 times faster than the lab's current flagship system, making it the Department of Energy's most powerful resource for training AI models and conducting advanced simulations. Jonathan Carter, associate lab director for computing sciences at Berkeley Lab, said the system's architecture was shaped by the evolving needs of researchers – many of whom are now using AI to augment simulations in areas like geothermal energy and quantum computing. Doudna's design reflects a broader shift in supercomputing. Traditional systems have prioritized 64-bit calculations for maximum numerical accuracy, but modern AI workloads often benefit from lower-precision operations (such as 16-bit or 8-bit) that enable faster processing speeds. Dion Harris, Nvidia's head of data center product marketing, noted that the flexibility to combine different levels of precision opens new frontiers for scientific research. The supercomputer will also be tightly integrated with the Energy Sciences Network, allowing researchers nationwide to stream data directly into Doudna for real-time analysis. Sudip Dosanjh, director of the National Energy Research Scientific Computing Center, described the new system as "designed to accelerate a broad set of scientific workflows."

Let’s start with one unambiguous fact: More children are diagnosed with autism today than in the early 1990s. According to a sweeping 2000 analysis by the Centers for Disease Control and Prevention, a range of 2–7 per 1,000, or roughly 0.5 percent of US children, were diagnosed with autism in the 1990s. That figure has risen to 1 in 35 kids, or roughly 3 percent.The apparent rapid increase caught the attention of people like Robert F. Kennedy Jr., who assumed that something had to be changing in the environment to drive it. In 2005, Kennedy, a lawyer and environmental activist at the time, authored an infamous essay in Rolling Stone that primarily placed the blame for the increased prevalence of autism on vaccines. (The article was retracted in 2011 as more studies debunked the vaccine-autism connection.) More recently, he has theorized that a mysterious toxin introduced in the late 1980s must be responsible. Now, as the nation’s top health official leading the Department of Health and Human Services, Kennedy has declared autism an “epidemic.” And, in April, he launched a massive federal effort to find the culprit for the rise in autism rates, calling for researchers to examine a range of suspects: chemicals, molds, vaccines, and perhaps even ultrasounds given to pregnant mothers. “Genes don’t cause epidemics. You need an environmental toxin,” Kennedy said in April when announcing his department’s new autism research project. He argued that too much money had been put into genetic research — “a dead end,” in his words — and his project would be a correction to focus on environmental causes. “That’s where we’re going to find an answer.”But according to many autism scientists I spoke to for this story, Kennedy is looking in exactly the wrong place. Three takeaways from this storyExperts say the increase in US autism rates is mostly explained by the expanding definitions of the condition, as well as more awareness and more screening for it.Scientists have identified hundreds of genes that are associated with autism, building a convincing case that genetics are the most important driver of autism’s development — not, as Health Secretary Robert F. Kennedy Jr. has argued, a single environmental toxin.Researchers fear Kennedy’s fixation on outside toxins could distract from genetic research that has facilitated the development of exciting new therapies that could help those with profound autism.Autism is a complex disorder with a range of manifestations that has long defied simple explanations, and it’s unlikely that we will ever identify a single “cause” of autism.But scientists have learned a lot in the past 50 years, including identifying some of the most important risk factors. They are not, as Kennedy suggests, out in our environment. They are written into our genetics. What appeared to be a massive increase in autism was actually a byproduct of better screening and more awareness. “The way the HHS secretary has been walking about his plans, his goals, he starts out with this basic assumption that nothing worthwhile has been done,” Helen Tager-Flusberg, a psychologist at Boston University who has worked with and studied children with autism for years, said. “Genes play a significant role. We know now that autism runs in families… There is no single underlying factor. Looking for that holy grail is not the best approach.”Doctors who treat children with autism often talk about how they wish they could provide easy answers to the families. The answers being uncovered through genetics research may not be simple per se, but they are answers supported by science.Kennedy is muddying the story, pledging to find a silver-bullet answer where likely none exists. It’s a false promise — one that could cause more anxiety and confusion for the very families Kennedy says he wants to help. Robert F. Kennedy Jr. speaks during a news conference at the Department of Health and Human Services in mid-April to discuss this agency’s efforts to determine the cause of autism. Alex Wong/Getty ImagesThe autism “epidemic” that wasn’tAutism was first described in 1911, and for many decades, researchers and clinicians confused the social challenges and language development difficulties common among those with the condition for a psychological issue. Some child therapists even blamed the condition on bad parenting. But in 1977, a study discovered that identical twins, who share all of their DNA, were much more likely to both be autistic than fraternal twins, who share no more DNA than ordinary siblings. It marked a major breakthrough in autism research, and pushed scientists to begin coalescing around a different theory: There was a biological factor.At the time, this was just a theory — scientists lacked the technology to prove those suspicions at the genetic level. And clinicians were also still trying to work out an even more fundamental question: What exactly was autism? For a long time, the criteria for diagnosing a person with autism was strictly based on speech development. But clinicians were increasingly observing children who could acquire basic language skills but still struggled with social communication — things like misunderstanding nonverbal cues or taking figurative language literally. Psychologists gradually broadened their definition of autism from a strict and narrow focus on language, culminating in a 2013 criteria that included a wide range of social and emotional symptoms with three subtypes — the autism spectrum disorder we’re familiar with today.Along the way, autism had evolved from a niche diagnosis for the severely impaired to something that encompassed far more children. It makes sense then, that as the broad criteria for autism expanded, more and more children would meet it, and autism rates would rise. That’s precisely what happened. And it means that the “epidemic” that Kennedy and other activists have been fixated on is mostly a diagnostic mirage. Historical autism data is spotty and subject to these same historical biases, but if you look at the prevalence of profound autism alone — those who need the highest levels of support — a clearer picture emerges. (There is an ongoing debate in the autism community about whether to use the terminology of “profound autism” or “high support needs” for those who have the most severe form of the condition.) In the ’80s and ’90s, low-support needs individuals would have been less likely to receive an autism diagnosis given the more restrictive criteria and less overall awareness of the disorder, meaning that people with severe autism likely represented most of the roughly 0.5 percent of children diagnosed with autism in the 1990s. (One large analysis from Atlanta examining data from 1996 found that 68 percent of kids ages 3 to 10 diagnosed with autism had an IQ below 70, the typical cutoff for intellectual disability.)By 2025, when about 3 percent of children are being diagnosed with autism, about one in four of those diagnosed are considered to have high-support needs autism, those with most severe manifestation of the condition. That would equal about 0.8 percent of all US children — which would be a fairly marginal increase from autism rates 30 years ago. Or look at it another way: In 2000, as many as 60 percent of the people being diagnosed with autism had an intellectual disability, one of the best indicators of high-support needs autism. In 2022, that percentage was less than 40 percent.As a recently published CDC report on autism prevalence among young children concluded, the increase in autism rates can largely be accounted for by stronger surveillance and more awareness among providers and parents, rather than a novel toxin or some other external factor driving an increase in cases.Other known risk factors — like more people now having babies later in their life, given that parental age is linked to a higher likelihood of autism — are more likely to be a factor than anything Kennedy is pointing at, experts say. “It’s very clear it’s not going to be one environmental toxin,” said Alison Singer, founder of the Autism Science Foundation and parent of a child with profound autism. “If there were a smoking gun, I think they would have found it.”While Kennedy has fixated on vaccines and environmental influences, scientists have gained more precision in mapping human genetics and identifying the biological mechanisms that appear to be a primary cause of autism. And that not only helps us understand why autism develops, but potentially puts long-elusive therapies within reach. It began with an accident in the 1990s. Steven Scherer, now director of the Center for Applied Genomics at the Hospital for Sick Children in Toronto, began his career in the late 1980s trying to identify the gene that caused cystic fibrosis — in collaboration with Francis Collins, who went on to lead the Human Genome Project that successfully sequenced all of the DNA in the human genome in the early 2000s. Scherer and Collins’s teams focused on chromosome 7, identified as a likely target by the primitive genetic research available at the time, a coincidence that would reorient Scherer’s career just a few years later, putting him on the trail of autism’s genetic roots.After four years, the researchers concluded that one gene within chromosome 7 caused cystic fibrosis. Soon after Scherer helped crack the code on cystic fibrosis in the mid-1990s, two parents from California called him: He was the world’s leading expert on chromosome 7, and recent tests had revealed that their children with autism had a problem within that particular chromosome.That very same week, Scherer says, he read the findings of a study by a group at Oxford University, which had looked at the chromosomes of families with two or more kids with autism. They, too, had identified problems within chromosome 7.“So I said, ‘Okay, we’re going to work on autism,’” Scherer told me. He helped coordinate a global research project, uniting his Canadian lab with the Oxford team and groups in the US to run a database that became the Autism Genome Project, still the world’s largest repository of genetic information of people with autism.They had a starting point — one chromosome — but a given chromosome contains hundreds of genes. And humans have, of course, 45 other chromosomes, any of which conceivably might play a role. So over the years, they collected DNA samples from thousands upon thousands of people with autism, sequenced their genes, and then searched for patterns. If the same gene is mutated or missing across a high percentage of autistic people, it goes on the list as potentially associated with the condition. Scientists discovered that autism has not one genetic factor, but many — further evidence that this is a condition of complex origin, in which multiple variables likely play a role in its development, rather than one caused by a single genetic error like sickle-cell anemia.Here is one way to think about how far we have come: Joseph Buxbaum, the director of the Seaver Autism Center for Research and Treatment at the Icahn School of Medicine at Mount Sinai in New York, entered autism genetics research 35 years ago. He recalls scientists being hopeful that they might identify a half dozen or so genes linked to autism.They have now found 500 genes — and Buxbaum told me he believed they might find a thousand before they are through. These genetic factors continue to prove their value in predicting the onset of autism: Scherer pointed to one recent study in which the researchers identified people who all shared a mutation in the SHANK3 gene, one of the first to be associated with autism, but who were otherwise unalike: They were not related and came from different demographic backgrounds. Nevertheless, they had all been diagnosed with autism.Researchers analyze the brain activity of a 14-year-old boy with autism as part of a University of California San Francisco study that involves intensive brain imaging of kids and their parents who have a rare chromosome disruption connected to autism. The study, the Simons Variation in Individuals Project, is a genetics-first approach to studying autism spectrum and related neurodevelopmental disorders. Michael Macor/San Francisco Chronicle via The Associated PressPrecisely how much genetics contributes to the development of autism remains the subject of ongoing study. By analyzing millions of children with autism and their parents for patterns in diagnoses, multiple studies have attributed about 80 percent of a person’s risk of developing autism to their inherited genetic factors. But of course 80 percent is not 100 percent. We don’t yet have the full picture of how or why autism develops. Among identical twins, for example, studies have found that in most cases, if one twin has high-support needs autism, the other does as well, affirming the genetic effect. But there are consistently a small minority of cases — 5 and 10 percent of twin pairs, Scherer told me — in which one twin has relatively low-support needs while the one requires a a high degree of support for their autism.Kennedy is not wholly incorrect to look at environmental factors — researchers theorize that autism may be the result of a complex interaction between a person’s genetics and something they experience in utero. Scientists in autism research are exploring the possible influence when, for example, a person’s mother develops maternal diabetes, high blood sugar that persists throughout pregnancy. And yet even if these other factors do play some role, the researchers I spoke to agree that genetics is, based on what we know now, far and away the most important driver.“We need to figure out how other types of genetics and also environmental factors affect autism’s development,” Scherer said. “There could be environmental changes…involved in some people, but it’s going to be based on their genetics and the pathways that lead them to be susceptible.”While the precise contours of Health Department’s new autism research project is still taking shape, Kennedy has that researchers at the National Institutes of Health will collect data from federal programs such as Medicare and Medicaid and somehow use that information to identify possible environmental exposures that lead to autism. He initially pledged results by September, a timeline that, as outside experts pointed out, may be too fast to allow for a thorough and thoughtful review of the research literature. Kennedy has since backed off on that deadline, promising some initial findings in the fall but with more to come next year.RFK Jr.’s autism commission research risks the accessibility of groundbreaking autism treatmentsIf Kennedy were serious about moving autism science forward, he would be talking more about genetics, not dismissing them. That’s because genetics is where all of the exciting drug development is currently happening.A biotech firm called Jaguar Gene Therapy has received FDA approval to conduct the first clinical trial of a gene therapy for autism, focused on SHANK3. The treatment, developed in part by one of Buxbaum’s colleagues, is a one-time injection that would replace a mutated or missing SHANK3 gene with a functional one. The hope is that the therapy would improve speech and other symptoms among people with high-needs autism who have also been diagnosed with a rare chromosomal deletion disorder called Phelan-McDermid syndrome; many people with this condition also have Autism spectrum disorder.The trial will begin this year with a few infant patients, 2 years old and younger, who have been diagnosed with autism. Jaguar eventually aims to test the therapy on adults over 18 with autism in the future. Patients are supposed to start enrolling this year in the trial, which is focused on first establishing the treatment’s safety; if it proves safe, another round of trials would start to rigorously evaluate its effectiveness.“This is the stuff that three or four years ago sounded like science fiction,” Singer said. “The conversation has really changed from Is this possible? to What are the best methods to do it? And that’s based on genetics.”Researchers at Mount Sinai have also experimented with delivering lithium to patients and seeing if it improves their SHANK3 function. Other gene therapies targeting other genes are in earlier stages of development. Some investigators are experimenting with CRISPR technology, the revolutionary new platform for gene editing, to target the problematic genes that correspond to the onset of autism.But these scientists fear that their work could be slowed by Kennedy’s insistence on hunting for environmental toxins, if federal dollars are instead shifted into his new project. They are already trying to subsist amid deep budget cuts across the many funding streams that support the institutions where they work. “Now we have this massive disruption where instead of doing really key experiments, people are worrying about paying their bills and laying off their staff and things,” Scherer said. “It’s horrible.” For the families of people with high-needs autism, Kennedy’s crusade has stirred conflicting emotions. Alison Singer, the leader of the Autism Science Foundation, is also the parent of a child with profound autism. When I spoke with her, I was struck by the bind that Kennedy’s rhetoric has put people like her and her family in. Singer told me profound autism has not received enough federal support in the past, as more emphasis was placed on individuals who have low support needs included in the expanding definitions of the disorder, and so she appreciates Kennedy giving voice to those families. She believes that he is sincerely empathetic toward their predicament and their feeling that the mainstream discussion about autism has for too long ignored their experiences in favor of patients with lower support needs. But she worries that his obsession with environmental factors will stymie the research that could yield breakthroughs for people like her child.“He feels for those families and genuinely wants to help them,” Singer said. “The problem is he is a data denier. You can’t be so entrenched in your beliefs that you can’t see the data right in front of you. That’s not science.”See More:

Ready for a front-row seat to the next scientific revolution? That’s the idea behind Doudna — a groundbreaking supercomputer announced today at Lawrence Berkeley National Laboratory in Berkeley, California. The system represents a major national investment in advancing U.S. high-performance computing (HPC) leadership, ensuring U.S. researchers have access to cutting-edge tools to address global challenges. “It will advance scientific discovery from chemistry to physics to biology and all powered by — unleashing this power — of artificial intelligence,” U.S. Energy Secretary Chris Wright (pictured above) said at today’s event. Also known as NERSC-10, Doudna is named for Nobel laureate and CRISPR pioneer Jennifer Doudna. The next-generation system announced today is designed not just for speed but for impact. Nobel laureate and CRISPR pioneer Jennifer Doudna speaking at today’s event in Berkeley, California. To her right, NVIDIA founder and CEO Jensen Huang and Paul Perez, senior vice president and senior technology fellow at Dell Technologies. Powered by Dell Technologies infrastructure with the NVIDIA Vera Rubin architecture, and set to launch in 2026, Doudna is tailored for real-time discovery across the U.S. Department of Energy’s most urgent scientific missions. It’s poised to catapult American researchers to the forefront of critical scientific breakthroughs, fostering innovation and securing the nation’s competitive edge in key technological fields. “I’m so proud that America continues to invest in this particular area,” said NVIDIA founder and CEO Jensen Huang. “It is the foundation of scientific discovery for our country. It is also the foundation for economic and technology leadership.” “It’s an incredible honor to be here,” Doudna said, adding she was “surprised and delighted” that a supercomputer would be named after her. “I think we’re standing at a really interesting moment in biology,” she added, with people with different skills coming together to address global issues. Designed to Accelerate Breakthroughs Unlike traditional systems that operate in silos, Doudna merges simulation, data and AI into a single seamless platform. “The Doudna supercomputer is designed to accelerate a broad set of scientific workflows,” said NERSC Director Sudip Dosanjh. “Doudna will be connected to DOE experimental and observational facilities through the Energy Sciences Network (ESnet), allowing scientists to stream data seamlessly into the system from all parts of the country and to analyze it in near real time.” It’s engineered to empower over 11,000 researchers with almost instantaneous responsiveness and integrated workflows, helping scientists explore bigger questions and reach answers faster than ever. “We’re not just building a faster computer,” said Nick Wright, advanced technologies group lead and Doudna chief architect at NERSC. “We’re building a system that helps researchers think bigger and discover sooner.” Here’s what Wright expects Doudna to advance: Fusion energy: Breakthroughs in simulation that unlocks clean fusion energy. Materials science: AI models that design new classes of superconducting materials. Drug discovery acceleration: Ultrarapid workflow that helps biologists fold proteins fast enough to outpace a pandemic. Astronomy: Real-time processing of data from the Dark Energy Spectroscopic Instrument at Kitt Peak to help scientists map the universe. Doudna is expected to outperform its predecessor, Perlmutter, by more than 10x in scientific output, all while using just 2-3x the power. This translates to a 3-5x increase in performance per watt, a result of innovations in chip design, dynamic load balancing and system-level efficiencies. AI-Powered Discovery at Scale Doudna will power AI-driven breakthroughs across high-impact scientific fields nationwide. Highlights include: AI for protein design: David Baker, a 2024 Nobel laureate, used NERSC systems to support his work using AI to predict novel protein structures, addressing challenges across scientific disciplines. AI for fundamental physics: Researchers like Benjamin Nachman are using AI to “unfold” detector distortions in particle physics data and analyze proton data from electron-proton colliders. AI for materials science: A collaboration including Berkeley Lab and Meta created “Open Molecules 2025,” a massive dataset for using AI to accurately model complex molecular chemical reactions. Researchers involved also use NERSC for their AI models. Real-Time Science, Real-World Impact Doudna isn’t a standalone system. It’s an integral part of scientific workflows. DOE’s ESnet will stream data from telescopes, detectors and genome sequencers directly into the machine with low-latency, high-throughput NVIDIA Quantum-X800 InfiniBand networking. This critical data flow is prioritized by intelligent quality-of-service mechanisms, ensuring it stays fast and uninterrupted, from input to insight. This will make the system incredibly responsive. At the DIII-D national fusion ignition facility, for example, data will stream control-room events directly into Doudna for rapid-response plasma modeling, so scientists can make adjustments in real time. “We used to think of the supercomputer as a passive participant in the corner,” Wright said. “Now it’s part of the entire workflow, connected to experiments, telescopes, detectors.” The Platform for What’s Next: Unlocking Quantum and HPC Workflows Doudna supports traditional HPC, cutting-edge AI, real-time streaming and even quantum workflows. The Mayall 4-Meter Telescope, which will be home to the Dark Energy Spectroscopic Instrument, seen at night at Kitt Peak National Observatory. This includes support for scalable quantum algorithm development and the codesign of future integrated quantum-HPC systems, using platforms like NVIDIA CUDA-Q. All of these workflows will run on the next-generation NVIDIA Vera Rubin platform, which will blend high-performance CPUs with coherent GPUs, meaning all processors can access and share data directly to support the most demanding scientific workloads. Researchers are already porting full pipelines using frameworks like PyTorch, the NVIDIA Holoscan software development kit, TensorFlow, NVIDIA cuDNN and NVIDIA CUDA-Q, all optimized for the system’s Rubin GPUs and NVIDIA NVLink architecture. Over 20 research teams are already porting full workflows to Doudna through the NERSC Science Acceleration Program, tackling everything from climate models to particle physics. This isn’t just about raw compute, it’s about discovery, integrated from idea to insight. Designed for Urgency Last year, AI-assisted science earned two Nobel Prizes. From climate research to pandemic response, the next breakthroughs won’t wait for better infrastructure. With deployment slated for 2026, Doudna is positioned to lead a new era of accelerated science. DOE facilities across the country, from Fermilab to the Joint Genome Institute, will rely on its capabilities to turn today’s questions into tomorrow’s breakthroughs. “This isn’t a system for one field,” Wright said. “It’s for discovery — across chemistry, physics and fields we haven’t imagined yet.” As Huang put it, Doudna is “a time machine for science.” It compresses years of discovery into days and gives the world’s toughest problems the power they’ve been waiting for. This post has been updated with comments from Thursday’s event at Lawrence Berkeley National Laboratory. 

Since the Chinese biophysicist He Jiankui was released from prison in 2022, he has sought to make a scientific comeback and to repair his reputation after a three-year incarceration for illegally creating the world’s first gene-edited children.  While he has bounced between cities, jobs, and meetings with investors, one area of visible success on his come-back trail has been his X.com account, @Jiankui_He, which has become his main way of spreading his ideas to the world. Starting in September 2022, when he joined the platform, the account stuck to the scientist’s main themes, including promising a more careful approach to his dream of creating more gene-edited children. “I will do it, only after society has accepted it,” he posted in August 2024. He also shared mundane images of his daily life, including golf games and his family. But over time, it evolved and started to go viral—first with a series of selfies accompanied by grandiose statements (“Every pioneer or prophet must suffer”), and then, in April of this year, it became particularly outrageous and even troll-like, blasting out bizarre messages (“Good morning bitches. How many embryos have you gene edited today?”). This has left observers unsure what to take seriously. Last month, in reply to MIT Technology Review’s questions about who was responsible for the account’s transformation into a font of clever memes, He emailed us back: “It’s thanks to Cathy Tie.” You may not be familiar with Tie but she’s no stranger to the public spotlight. A former Thiel fellow, she is a partner in the attention-grabbing Los Angeles Project, which promised to create glow-in-the-dark pets. Over the past several weeks, though, the 29-year-old Canadian entrepreneur has started to get more and more attention as the new wife to (and apparent social media mastermind behind) He Jiankui. On April 15, He announced a new venture, Cathy Medicine, that would take up his mission of editing human embryos to create people resistant to diseases like Alzheimer’s or cancer. Then just a few days later, on April 18, He and Tie announced that they got married, posting pictures of themselves in traditional Chinese wedding attire. But now, Tie says that just a month after marrying “the most controversial scientist in the world,” her plans to relocate from Los Angeles to Beijing to be with He are in disarray; she says she’s been denied entry to China and the two “may never see each other again,” as He’s passport is being held by Chinese authorities and he can’t leave the country. Reached by phone in Manila, Tie said authorities in the Philippines intercepted her during a layover on May 17 and told her she couldn’t board a plane to China, where she was born and where she says she has a valid 10-year visa. She claims they didn’t say why but told her she is likely “on a watch list.” (MIT Technology Review could not independently confirm Tie’s account.)  “While I’m concerned about my marriage, I am more concerned about what this means for humanity and the future of science,” Tie posted to her own X account. A match made in gene-editing heaven The romance between He and Tie has been playing out in public over the past several weeks through a series of reveals on He’s X feed, which had already started going viral late last year thanks to his style of posting awkward selfies alongside maxims about the untapped potential of heritable gene editing, or changing people’s DNA when they’re just embryos in an IVF dish.  “Human [sic] will no longer be controlled by Darwin’s evolution,” He wrote in March. That post, which showed him standing in an empty lab, gazing into the distance, garnered 9.7 million views. And then, a week later for 13.3 million: “Ethics is holding back scientific innovation and progress.”  In April, the feed started to change even more drastically.  He’s posts became increasingly provocative, with better English and a unique sensibility of online culture. “Stop asking for cat girls. I’m trying to cure disease,” the account posted on April 15. Two days later, the account followed-up: “I literally went to prison for this shit.”  This shift coincided with the development of his romance with Tie. Tie told us she has visited China three times this year, including a three-week stint in April when she and He got married after a whirlwind romance. She bought him a silver wedding ring made up of intertwined DNA strands.  The odd behavior on He’s X feed and the sudden marriage have left followers wondering if they are watching a love story, a new kind of business venture, or performance art. It might be all three.  A wedding photo posted by Tie on Chinese social media platform Rednote shows the couple sitting at a banquet hall, with a small number of guests. MIT Technology Review has been able to identify several people who attended: Cai Xilei, He’s criminal attorney; Liu Haiyan, an investor and former business partner of He; and Darren Zhu, an artist and Thiel fellow who is making a “speculative” documentary about the biophysicist that will blur the boundaries of fiction and reality. In the phone interview, Tie declined to say if she and He are legally married. Tie also confirmed she celebrated a wedding less than one year ago with someone else in California, in July of 2024, but noted they broke up after a few months; she also declined to describe the legal status of that marriage. In the phone call, Tie emphasized that her relationship with He is genuine: “I wouldn’t marry him if I wasn’t in love with him.” An up and comer Years before Tie got into a relationship with He, she was getting plenty of attention in her own right. She became a Thiel Fellow in 2015, when she was just 18. That program, started by billionaire Peter Thiel, gave her a grant of $100,000 to drop out of the University of Toronto and start a gene testing company, Ranomics.  Soon, she began appearing on the entrepreneurs circuit, a “wunderkind” who was featured on a Forbes “30 Under 30” list in 2018 and was presented as an up-and-coming venture capitalist on CNN that same year. In 2020, she started her second company, Locke Bio, that focuses on online telemedicine. Like Thiel, Tie has also staked out contrarian positions. She’s called mainstream genomics a scam and described entrepreneurship as a way to escape the hidebound practices of academia and bioethics. “Starting companies is my preferred form of art,” she posted in 2022, linking to an interview on CNBC.  By February 2025, Tie was ready to announce another new venture, the Los Angeles Project, a stealth company she had incorporated in 2023 under her legal name, Cheng Cheng Tie. The company, started with the Austin-based biohacker and artist Josie Zayner, says it will try to modify animal embryos, including to make fluorescent glow-in-the-dark rabbits as pets. The Los Angeles Project revels in explicitly transgressive aims for embryo editing, including a plan to add horn genes to horse embryos to make a unicorn. That’s consistent with Zayner’s past stunts, which include injecting herself with CRISPR during a livestream. “This is a company that should not exist,” Zayner said in announcing the newly public project. Although the Los Angeles Project has only a tiny staff with uncertain qualifications, it did raise $1 million from the 1517 fund, a venture group that supports “dropouts” and whose managers previously ran the Thiel Fellowship.  Asked for his assessment of Tie, Michael Gibson, a 1517 partner, said in an email that he thinks Tie is “not just exceptional, but profoundly exceptional.” He sent along a list of observations he’d jotted down about Tie before funding her company, which approvingly noted her “hyper-fluent competence” and “low need for social approval. Thoughts & actions routinely unconventional.”  A comeback story He first gained notoriety in 2018, when he and co-workers at the Southern University of Science & Technology in Shenzhen, injected the CRISPR gene-editor into several viable human embryos, and then transferred these into volunteers, leading to the birth of three girls who he claimed would be resistant to HIV. A subsequent Chinese investigation found he’d practiced medicine illegally while “pursuing fame and fortune.” A court later sentenced him to three years in prison. He has never apologized for his experiments, except to say he acted “too quickly” and to express regret for the trouble he’d caused his former wife and two daughters. (According to a leaked WeChat post by his ex-wife, she divorced him in 2024 “because of a major fault on his side.”) Since his release from prison, He has sought to restart his research and convince people that he should be recognized as the “Chinese Darwin,” not “China’s Frankenstein,” as the press once dubbed him.  But his comeback has been bumpy. He lost a position at Wuchang University of Technology, a small private university in Hubei province, after some negative press. In February 2024, He posted that his application for funding from the Muscular Dystrophy Association was rejected. Last September, he even posted pictures of his torn shirt—which he said was the result of an assault by jealous rivals. One area of clear success, though, was the growing reach of his X profile, which today has ballooned to more than 130,000 followers. And as his public profile rose, some started encouraging He to find ways to cash in. Andrew Hessel, a futurist and synthetic biologist active in US ethics debates, says he tried to get He invited to give a TED Talk. “His story is unique, and I wanted to see his story get more widespread attention, if only as a cautionary tale,” Hessel says. “I think he is a lightning rod for a generation of people working in life sciences.” Later, Hessel says he sent him information on how to join X’s revenue-sharing program. “I said, ‘You have a powerful voice.’ Have you looked into monetization?” Hessel says. By last fall, He was also welcoming visitors to what he called a new lab in Beijing. One person who took him up on the offer was Steve Hsu, a Michigan State physics professor who has started several genetics companies and was visiting Beijing.  They ended up talking for hours. Hsu says that He expressed a desire to move to the US and start a company, and that he shared his idea for conducting a clinical trial of embryo editing in South Africa, possibly for the prevention of HIV.  Hsu says he later arranged an invitation for He to give a lecture in the United States. “You are a little radioactive, but things are opening up,” Hsu told him. But He declined the offer because the Chinese government is holding his passport—a common tactic it uses to restrict the movement of sensitive or high-profile figures—and won’t return it to him. “He doesn’t even know why. He literally doesn’t know,” says Hsu. “According to the law, they should give it back to him.” A curious triangle Despite any plans by He and Tie to advance the idea, creating designer babies is currently illegal in most of the world, including China and the US. Some experts, however, fret that forbidding the technology will only drive it underground and make it attractive to biohackers or scientists outside the mainstream.  That’s one reason Tie’s simultaneous connection to two notable biotech renegades—He and Zayner—is worth watching. “There is clearly a triangle forming in some way,” says Hessel. With Tie stuck outside China, and He being kept inside the country, their new gene-editing venture, Cathy Medicine, faces an uncertain future. Tie has posted previously on Rednote that she was “helping Dr. He open up the U.S. market,” and was planning to return to the US with He for scientific research. But when we spoke on the phone, Tie declined to disclose their next steps and said their predicament means the project is “out of the window now.” But even as the couple remains separated, their social media game is stronger than ever. As she waited in Manila, Tie sought help from friends and followers, even the entire internet. She blasted out a tweet to “crypto people” calling them “too pussy to stand up for things when it matters.” Within hours, someone had created a memecoin called $GENE as a way for the public to support the couple.  On May 20, Tie posted on X claiming that the amount donated to them is now worth almost $2 million. “I may need to retract my last statement about crypto,” wrote Tie.  He’s X account also retweeted to express support: “I only want to reunite with my wife @CathyTie, and continue my gene editing research.” He added the hashtag $GENE.

CRISPR (short for Clustered Regularly Interspaced Short Palindromic Repeats) — the genetic equivalent of a word processor — has received its most powerful upgrade yet: the ability to insert an entire gene at the most potentially effective spot, according to an article in the journal Science.This marks a key step in cell and gene therapy, all of which aim to treat illnesses by making corrections or additions to the “misspelled” genes that can lead to disease.Before CRISPR, delivering genes inside of neutered viruses was thought to be the answer. It sometimes worked, but often the new genetic word would be flooded into the body, inserted at random. Sometimes it would land in the right spot, other times it would miss its target. And worst of all, that approach can lead to a potentially deadly immune response.The Rise of CRISPRWhen CRISPR debuted in 2012, it was thought to provide both more specificity and control. It is essentially the genetic equivalent of a “search and replace” command in a word processor, with the ability to find, then snip out faulty DNA within one gene, using what many researchers call “molecular scissors.” Its innovators were awarded the Nobel Prize in Chemistry in 2020.However, despite incredible potential, that approach still has some limitations. The “scissors” can sometimes snip the wrong part of the targeted DNA sequence. This could lead to either incomplete repair or the inadvertent admission of a harmful mutation. It can also only fix one error in a single gene at a time.Despite those “software bugs” and limitations, early versions of CRISPR have shown promise. The approach was used to edit genes in six patients with a rare genetic disorder in 2022. More recently, scientists used the system to deliver for the first time a treatment tailored to a specific patient, a baby boy with a rare metabolic disorder.CRISPR Upgrades The multiple components of the evoCAST gene editor grasping a strand of DNA (red). (Image Cred: George Lampe (Columbia University Irving Medical Center))The new version shows promise to be even more effective. Since it doesn’t cut out any existing DNA, it is less likely to inadvertently add mutations or errors. It is much more specific than either virus-based gene therapy or earlier CRISPR approaches. And delivering an entire correct gene is considered a safer, more effective approach than cutting and replacing portions of an existing one.The update essentially involves the addition of guide molecules called “CRISPR-associated transposases (CASTs).” These bacterial systems “lead” CRISPR to specific sites, so the correct gene is more likely to be integrated and activated. The tool's developers named it “evoCAST.”Also, existing gene therapy strategies, as well as the early CRISPR work in humans, were focused on diseases with errors in only one gene. Although there are many such diseases, each one affects relatively few people, compared to more common diseases that are thought to be the result of multiple genetic mutations.“Hundreds to thousands of different mutations in the CFTR gene can cause cystic fibrosis, for example, so an inordinate number of distinct gene editing drugs would be needed to ensure each patient could be treated,” Samuel Sternberg, a researcher at Columbia University and an author of the paper, said in a press release. “Instead, something like evoCAST could enable a single gene therapy that inserts a complete and healthy gene into the patient’s genome."CRISPR's Future The researchers will continue to test the evoCAST system in animals modelled to exhibit certain human diseases. As they do so, they intend to tweak and debug the system so it can be even more accurate and effective. But their biggest challenge is the same one that faced early gene therapy researchers: targeted delivery.“How do we actually get these tools and their payloads into the cells or tissues of interest?” Sternberg said in a press release. “That’s a challenge that many of us in the field are facing.”This article is not offering medical advice and should be used for informational purposes only.Article SourcesOur writers at Discovermagazine.com use peer-reviewed studies and high-quality sources for our articles, and our editors review for scientific accuracy and editorial standards. Review the sources used below for this article:The Nobel Prize. Genetic scissors: a tool for rewriting the code of lifeBefore joining Discover Magazine, Paul Smaglik spent over 20 years as a science journalist, specializing in U.S. life science policy and global scientific career issues. He began his career in newspapers, but switched to scientific magazines. His work has appeared in publications including Science News, Science, Nature, and Scientific American.